Navitoclax treatment has already been shown to improve blood fasting glucose levels in a pharmacological type 2 diabetes model of treatment with the insulin receptor antagonist S961 [5]; but it had never been tested with a mouse model of DIO, as presented here. This evidence concerns the gene INSR and type 2 diabetes mellitus.